Lugano Financial Advisors SA (LFA)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$326K Buy
1,295
+55
+4% +$11.8K 0.2% 58
2026
Q1
$267K Hold
1,240
0.14% 66
2025
Q4
$281K Hold
1,240
0.15% 67
2025
Q3
$285K Hold
1,240
0.15% 65
2025
Q2
$228K Hold
1,240
0.14% 67
2025
Q1
$260K Buy
1,240
+40
+3% +$7.78K 0.18% 60
2024
Q4
$213K Hold
1,200
0.14% 65
2024
Q3
$237K Hold
1,200
0.16% 67
2024
Q2
$206K Hold
1,200
0.16% 62
2024
Q1
$219K Hold
1,200
0.16% 63
2023
Q4
$186K Sell
1,200
-500
-29% -$72.9K 0.15% 57
2023
Q3
$253K Sell
1,700
-1,688
-50% -$248K 0.22% 47
2023
Q2
$456K Buy
3,388
+2,900
+594% +$425K 0.3% 44
2023
Q1
$77.8K Hold
488
0.06% 78
2022
Q4
$78.9K Buy
+488
New +$74.8K 0.06% 77
2022
Q1
Sell
-732
Closed -$99K 109
2021
Q4
$99K Buy
+732
New +$86.5K 0.06% 71

Other funds holding ABBV

Lugano Financial Advisors SA (LFA)'s ABBV Position: Q2 2026 in Review

Lugano Financial Advisors SA (LFA) increased its AbbVie (ABBV) stake by 4.4% in Q2 2026, buying an estimated $11.8K and bringing the position to 1,295 shares worth $326K. The position accounts for 0.2% of the portfolio, ranked #58.

Lugano Financial Advisors SA (LFA) first reported a position in ABBV in Q4 2021 and has held it in 16 quarters since. The position peaked at $456K in Q2 2023. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lugano Financial Advisors SA (LFA) held 1,295 shares of AbbVie worth $326K as of Q2 2026.
  • Lugano Financial Advisors SA (LFA) bought 55 AbbVie shares in Q2 2026, an estimated $11.8K.
  • AbbVie made up 0.2% of Lugano Financial Advisors SA (LFA)'s portfolio in Q2 2026, its #58 holding.
  • Lugano Financial Advisors SA (LFA) first reported a position in AbbVie in Q4 2021 and has held it in 16 quarters since.
  • Lugano Financial Advisors SA (LFA)'s AbbVie position peaked at $456K in Q2 2023.
  • 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lugano Financial Advisors SA (LFA)'s 13F filing for Q2 2026, filed 28 Jul 2026.